{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:27:53Z","timestamp":1787243273018,"version":"build-2736575974"},"reference-count":75,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Severe asthma imposes a significant burden on public health worldwide, mainly due to its morbidity and high cost. The management of severe asthma has dramatically changed in the past few years with the introduction of biologics. Zero exacerbations, zero systemic corticosteroids, better asthma control, and better lung function are the outcomes that the era of biologics has made attainable in a large proportion of severe asthmatics, ending up in a better quality of life. Still, even today, the changes at the tissue level that reflect these outcomes are not that clear. As a chronic inflammatory disease, asthma often involves airway remodeling in its severe forms; endobronchial biopsies may provide critical insights into these tissue-level changes before and after biologic treatment. However, bronchoscopy is an invasive tool for severe asthma, thus limiting its use in daily clinical practice. This review focuses on summarizing the changes that biologics exert in biopsies obtained from severe asthmatics under biological treatment, providing an opportunity to shed light on what really happens there where it is not easy to see, and especially on what does not happen in patients under biologics who fail to respond as expected. Moreover, the armamentarium of biomarkers used for making the proper choice in patients eligible for more than one biologic needs to be enriched. Biopsy-related markers could be an ideal adjunct to the current ones\u2014blood eosinophils, FeNO, and IgE\u2014to assist the clinician to choose the right biologic for the right patient with severe asthma to achieve disease remission.<\/jats:p>","DOI":"10.3390\/ijms26167692","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T15:30:52Z","timestamp":1754667052000},"page":"7692","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Role of Endobronchial Biopsies in Evaluating Biologic Therapy Response in Severe Asthma"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-6800","authenticated-orcid":false,"given":"Agamemnon","family":"Bakakos","sequence":"first","affiliation":[{"name":"1st Department of Respiratory Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Ampazis","sequence":"additional","affiliation":[{"name":"Respiratory Department, Cavan & Monaghan Hospital & Chronic Disease Management Hub, HSE & RCSI University of Medicine, H12 Y7W1 Cavan, Ireland"},{"name":"Royal College of Surgeons in Ireland, University of Medicine & Health Sciences, D02 YN77 Dublin 2, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9708-3241","authenticated-orcid":false,"given":"Andriana I.","family":"Papaioannou","sequence":"additional","affiliation":[{"name":"1st Department of Respiratory Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-9922","authenticated-orcid":false,"given":"Stelios","family":"Loukides","sequence":"additional","affiliation":[{"name":"2nd Department of Respiratory Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9256-9656","authenticated-orcid":false,"given":"Petros","family":"Bakakos","sequence":"additional","affiliation":[{"name":"1st Department of Respiratory Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"ref_1","unstructured":"(2025, June 15). Global Strategy for Asthma Management and Prevention, 2024. Available online: www.ginasthma.org."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Holguin, F., Cardet, J.C., Chung, K.F., Diver, S., Ferreira, D.S., Fitzpatrick, A., Gaga, M., Kellermeyer, L., Khurana, S., and Knight, S. (2020). Management of severe asthma: A European Respiratory Society\/American Thoracic Society guideline. Eur. Respir. J., 55.","DOI":"10.1183\/13993003.00588-2019"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic Therapies for Severe Asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International, ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chest.2019.10.009","article-title":"Recent Advances in Severe Asthma: From Phenotypes to Personalized Medicine","volume":"157","author":"Schoettler","year":"2020","journal-title":"Chest"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41533-023-00330-1","article-title":"Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update","volume":"33","author":"Levy","year":"2023","journal-title":"NPJ Prim. Care Respir. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: Long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J. Asthma Allergy"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Bakakos, P., Kostikas, K., Loukides, S., Makris, M., Papadopoulos, N.G., Steiropoulos, P., Tryfon, S., and Zervas, E. (2022). Reducing Tolerance for SABA and OCS towards the Extreme Ends of Asthma Severity. J. Pers. Med., 12.","DOI":"10.3390\/jpm12030504"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17476348.2018.1505507","article-title":"The concepts of asthma endotypes and phenotypes to guide current and novel treatment strategies","volume":"12","author":"Ozdemir","year":"2018","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/JAA.S378505","article-title":"Retrospective Claims Database Study to Clarify Disease Burden of Severe Asthma Patients with Type 2 High or Low Inflammation","volume":"16","author":"Harada","year":"2023","journal-title":"J. Asthma Allergy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"00483","DOI":"10.1183\/23120541.00483-2022","article-title":"Distribution of type 2 biomarkers and association with severity, clinical characteristics and comorbidities in the BREATHE real-life asthma population","volume":"9","author":"Frossing","year":"2023","journal-title":"ERJ Open Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","article-title":"Eosinophilic and Noneosinophilic Asthma","volume":"197","author":"Carr","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/thx.2009.126722","article-title":"Effects of steroid therapy on inflammatory cell subtypes in asthma","volume":"65","author":"Cowan","year":"2010","journal-title":"Thorax"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1183\/13993003.01196-2014","article-title":"Novel concepts in airway inflammation and remodelling in asthma","volume":"46","author":"Saglani","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/cea.13086","article-title":"New and emerging drug treatments for severe asthma. Clinical and experimental allergy","volume":"48","author":"Diver","year":"2018","journal-title":"J. Br. Soc. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovic","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1398-9995.2008.01881.x","article-title":"Eosinophils in bronchial mucosa of asthmatics after allergen challenge: Effect of anti-IgE treatment","volume":"64","author":"Evertse","year":"2009","journal-title":"Allergy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/039463201202500217","article-title":"Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients","volume":"25","author":"Riccio","year":"2012","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.imlet.2014.08.010","article-title":"Proteomics of bronchial biopsies: Galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients","volume":"162","author":"Mauri","year":"2014","journal-title":"Immunol. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1183\/13993003.01501-2015","article-title":"Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma","volume":"48","author":"Pillai","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cea.13248","article-title":"Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy","volume":"49","author":"Huang","year":"2019","journal-title":"Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13223-019-0378-6","article-title":"Bronchoscopy-guided bronchial epithelium sampling as a tool for selecting the optimal biologic treatment in a patient with severe asthma: A case report","volume":"15","author":"Kuo","year":"2019","journal-title":"Allergy Asthma Clin. Immunol. Off. J. Can. Soc. Allergy Clin. Immunol."},{"key":"ref_31","first-page":"468","article-title":"Omalizumab may decrease the thickness of the reticular basement membrane and fibronectin deposit in the bronchial mucosa of severe allergic asthmatics","volume":"57","author":"Zastrzezynska","year":"2020","journal-title":"J. Asthma Off. J. Assoc. Care Asthma"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bakakos, A., Loukides, S., and Bakakos, P. (2019). Severe Eosinophilic Asthma. J. Clin. Med., 8.","DOI":"10.3390\/jcm8091375"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/09031936.00201813","article-title":"Importance of concomitant local and systemic eosinophilia in uncontrolled asthma","volume":"44","author":"Schleich","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1164\/rccm.201611-2234OC","article-title":"Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma","volume":"196","author":"Kelly","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaci.2024.10.024","article-title":"Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype","volume":"155","author":"Domvri","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_38","first-page":"e85","article-title":"Airway remodelling in asthma: From benchside to clinical practice","volume":"17","author":"Bergeron","year":"2010","journal-title":"Can. Respir. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1172\/JCI17974","article-title":"Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics","volume":"112","author":"Phipps","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Taille, F.H.C., Heddebaut, N., Dupin, C., Le Guen, P., Le Brun, M., Pot\u00e9, N., Cazes, A., Roy, C., Dupont, A., and L\u00e9tuv\u00e9, S. (2024). Impact of Mepolizumab on Airway Remodelling in Severe Eosinophilic Asthma [abstract]. Am. J. Respir. Crit. Care Med., 209.","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A1051"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Dagher, R., Kumar, V., Copenhaver, A.M., Gallagher, S., Ghaedi, M., Boyd, J., Newbold, P., Humbles, A.A., and Kolbeck, R. (2022). Novel mechanisms of action contributing to benralizumab\u2019s potent anti-eosinophilic activity. Eur. Respir. J., 59.","DOI":"10.1183\/13993003.04306-2020"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1164\/rccm.202003-0729LE","article-title":"Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma","volume":"202","author":"Moran","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S2213-2600(24)00299-6","article-title":"Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): A double-blind, double-dummy, active placebo-controlled randomised trial","volume":"13","author":"Ramakrishnan","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Chachi, L., Diver, S., Kaul, H., Rebelatto, M.C., Boutrin, A., Nisa, P., Newbold, P., and Brightling, C. (2019). Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma. Eur. Respir. J., 54.","DOI":"10.1183\/13993003.00930-2019"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gauvreau, G.M., Sehmi, R., FitzGerald, J.M., Leigh, R., Cockcroft, D.W., Davis, B.E., Mayers, I., Boulet, L.P., Al-Sajee, D., and Salter, B.M. (2024). Benralizumab for allergic asthma: A randomised, double-blind, placebo-controlled trial. Eur. Respir. J., 64.","DOI":"10.1183\/13993003.00512-2024"},{"key":"ref_47","unstructured":"(2025, June 15). A Phase 4, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics. Available online: https:\/\/www.astrazenecaclinicaltrials.com\/study\/D3250C00059\/."},{"key":"ref_48","unstructured":"(2025, June 15). Effect of Benralizumab on Airway Remodeling in Asthma (BENRAMOD), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04365205."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of Dupilumab on Blood Eosinophil Counts in Patients with Asthma, Chronic Rhinosinusitis with Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_50","unstructured":"(2025, June 15). Evaluation of Dupilumab\u2019s Effects on Airway Inflammation in Patients with Asthma (EXPEDITION), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02573233."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bini, F., Bodini, B.D., Cristiano, A., and Vaghi, A. (2023). Persistence of eosinophils in bronchial mucosa biopsies in patients treated with dupilumab for 6 months. Eur. Respir. J., 62.","DOI":"10.1183\/13993003.congress-2023.PA4718"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/13543784.2019.1672657","article-title":"Tezepelumab: A novel biological therapy for the treatment of severe uncontrolled asthma","volume":"28","author":"Marone","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma","volume":"384","author":"Corren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/all.15197","article-title":"Baseline type 2 biomarker levels and response to tezepelumab in severe asthma","volume":"77","author":"Corren","year":"2022","journal-title":"Allergy"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2101296","DOI":"10.1183\/13993003.01296-2021","article-title":"The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)","volume":"59","author":"Sverrild","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41390-018-0239-x","article-title":"Anti-thymic stromal lymphopoietin antibody suppresses airway remodeling in asthma through reduction of MMP and CTGF","volume":"86","author":"Lin","year":"2019","journal-title":"Pediatr. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/cea.14153","article-title":"High proportion of inflammatory CD62L(low) eosinophils in blood and nasal polyps of severe asthma patients","volume":"53","author":"Matucci","year":"2023","journal-title":"Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1111\/all.15909","article-title":"Blood CD62L(low) inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab","volume":"78","author":"Vultaggio","year":"2023","journal-title":"Allergy"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"Mesnil","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Calven, J., Ax, E., and Radinger, M. (2020). The Airway Epithelium-A Central Player in Asthma Pathogenesis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21238907"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Varricchi, G., Brightling, C.E., Grainge, C., Lambrecht, B.N., and Chanez, P. (2024). Airway remodelling in asthma and the epithelium: On the edge of a new era. Eur. Respir. J., 63.","DOI":"10.1183\/13993003.01619-2023"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41577-020-00477-9","article-title":"Regulation of immune responses by the airway epithelial cell landscape","volume":"21","author":"Hewitt","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/17476348.2023.2262920","article-title":"Epithelial alarmins: A new target to treat chronic respiratory diseases","volume":"17","author":"Nedeva","year":"2023","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Porsbjerg, C., Nieto-Fontarigo, J.J., Cerps, S., Ramu, S., Menzel, M., Hvidtfeldt, M., Silberbrandt, A., Frossing, L., Klein, D., and Sverrild, A. (2022). Phenotype and severity of asthma determines bronchial epithelial immune responses to a viral mimic. Eur. Respir. J., 60.","DOI":"10.1183\/23120541.LSC-2022.27"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1111\/all.15473","article-title":"Biologics and airway remodeling in severe asthma","volume":"77","author":"Varricchi","year":"2022","journal-title":"Allergy"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/14728222.2023.2177533","article-title":"Airway smooth muscle in contractility and remodeling of asthma: Potential drug target mechanisms","volume":"27","author":"Khalfaoui","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Hough, K.P., Curtiss, M.L., Blain, T.J., Liu, R.M., Trevor, J., Deshane, J.S., and Thannickal, V.J. (2020). Airway Remodeling in Asthma. Front. Med., 7.","DOI":"10.3389\/fmed.2020.00191"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Hallstrand, T.S., Leuppi, J.D., Joos, G., Hall, G.L., Carlsen, K.H., Kaminsky, D.A., Coates, A.L., Cockcroft, D.W., Culver, B.H., and Diamant, Z. (2018). ERS technical standard on bronchial challenge testing: Pathophysiology and methodology of indirect airway challenge testing. Eur. Respir. J., 52.","DOI":"10.1183\/13993003.01033-2018"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.chest.2024.11.045","article-title":"The Role of Bronchial Biopsy in the Prediction of Response to Biologic Therapy in Severe Uncontrolled Asthma: A Prospective Study","volume":"167","author":"Cosio","year":"2025","journal-title":"Chest"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1164\/rccm.202110-2265OC","article-title":"Mucus Plugs Persist in Asthma, and Changes in Mucus Plugs Associate with Changes in Airflow over Time","volume":"205","author":"Tang","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_74","first-page":"1","article-title":"Response to Monoclonal Antibodies in Asthma: Definitions, Potential Reasons for Failure, and Therapeutic Options for Suboptimal Response","volume":"33","author":"Cisneros","year":"2023","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12931-023-02415-4","article-title":"The effects of benralizumab on airway geometry and dynamics in severe eosinophilic asthma: A single-arm study design exploring a functional respiratory imaging approach","volume":"24","author":"Genofre","year":"2023","journal-title":"Respir. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/16\/7692\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:26:51Z","timestamp":1760034411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/16\/7692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":75,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["ijms26167692"],"URL":"https:\/\/doi.org\/10.3390\/ijms26167692","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]}}}